Page 32 - Read Online

Feng et al. Hepatoma Res 2021;7:3 I http://dx.doi.org/10.20517/2394-5079.2020.107 Page 13 of 15

14. Diehl L, Schurich A, Grochtmann R, Hegenbarth S, Chen L, Knolle PA. Tolerogenic maturation of liver sinusoidal endothelial cells
promotes B7-homolog 1-dependent CD8+ T cell tolerance. Hepatology 2008;47:296-305.
15. Schildberg FA, Hegenbarth SI, Schumak B, Scholz K, Limmer A, Knolle PA. Liver sinusoidal endothelial cells veto CD8 T cell activation
by antigen-presenting dendritic cells. Eur J Immunol 2008;38:957-67.
16. Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. In: Terjung R, editor. Comprehensive physiology.
Hoboken: John Wiley & Sons, Inc.; 2013.
17. Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010;10:753-66.
18. You Q, Cheng L, Kedl RM, Ju C. Mechanism of T cell tolerance induction by murine hepatic Kupffer cells. Hepatology 2008;48:978-90.
19. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral
blood of patients with hepatocellular carcinoma. Cancer Res 2005;65:2457-64.
20. Dou L, Ono Y, Chen YF, Thomson AW, Chen XP. Hepatic dendritic cells, the tolerogenic liver environment, and liver disease. Semin
Liver Dis 2018;38:170-80.
21. Severi T, van Malenstein H, Verslype C, van Pelt JF. Tumor initiation and progression in hepatocellular carcinoma: risk factors,
classification, and therapeutic targets. Acta Pharmacol Sin 2010;31:1409-20.
22. Qin LX. Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma. Cancer Microenviron
2012;5:203-9.
23. Cancer Genome Atlas Research Network. Cancer Genome Atlas Research Network. Comprehensive and integrative genomic
characterization of hepatocellular carcinoma. Cell 2017;169:1327-41.e23.
24. Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular
features. Gastroenterology 2017;153:812-26.
25. Behboudi S, Boswell S, Williams R. Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular
carcinoma. Liver Int 2010;30:521-6.
26. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma
patients. Gastroenterology 2007;132:2328-39.
27. Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis 2019;39:26-42.
28. Liu CY, Chen KF, Chen PJ. Treatment of liver cancer. Cold Spring Harb Perspect Med 2015;5:a021535.
29. Jadid FZ, Chihab H, Alj HS, et al. Control of progression towards liver fibrosis and hepatocellular carcinoma by SOCS3 polymorphisms
in chronic HCV-infected patients. Infect Genet Evol 2018;66:1-8.
30. Kudo M. Immuno-oncology in hepatocellular carcinoma: 2017 Update. Oncology 2017;93 Suppl 1:147-59.
31. Chuang W, Liu H, Chang W. Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor
invasion. Cancer 1990;65:926-30.
32. Wu Y, Kuang DM, Pan WD, et al. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated
by CD48/2B4 interactions. Hepatology 2013;57:1107-16.
33. Abril-Rodriguez G, Ribas A. SnapShot: immune checkpoint inhibitors. Cancer Cell 2017;31:848.e1.
34. Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
Nature 2018;560:382-6.
35. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med
2015;372:320-30.
36. El-khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label,
non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
37. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
(KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
38. Kudo M. Molecular targeted therapy for hepatocellular carcinoma: where are we now? Liver Cancer 2015;4:I-VII.
39. Zhang B, Finn RS. Personalized clinical trials in hepatocellular carcinoma based on biomarker selection. Liver Cancer 2016;5:221-32.
40. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE):
a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
41. Yoo C, Park JW, Kim YJ, et al. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib
in Korean patients with hepatocellular carcinoma. Invest New Drugs 2019;37;567-72.
42. Yoo C, Ryu YM, Kim SY, et al. Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in
advanced gastrointestinal stromal tumours. Br J Cancer 2019;121;819-26.
43. Titano J, Noor A, Kim E. Transarterial chemoembolization and radioembolization across barcelona clinic liver cancer stages. Semin
Intervent Radiol 2017;34;109-15.
44. Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a
subclassification to facilitate treatment decisions. Semin Liver Dis 2012;32;348-59.
45. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label,
non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
46. Yau T, Hsu C, Kim TY, et al. Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced Asian cohort analysis. J Hepatol
2019;71;543-52.
47. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014;14:559-67.
48. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated